Analyst Rating Update on OraSure Technologies (OSUR)

OraSure Technologies (NASDAQ:OSUR) : 2 analysts are covering OraSure Technologies (NASDAQ:OSUR) and their average rating on the stock is 2, which is read as a Buy. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

For the current week, the company shares have a recommendation consensus of Buy. Also, In the latest statement by the brokerage house, Raymond James downgrades its outlook on OraSure Technologies (NASDAQ:OSUR). The current rating of the shares is Market Perform, according to the research report released by the firm. Previously, the company had a rating of Outperform. The rating by the firm was issued on June 13, 2016.

OraSure Technologies (NASDAQ:OSUR): stock turned positive on Tuesday. Though the stock opened at $6.6, the bulls momentum made the stock top out at $6.83 level for the day. The stock recorded a low of $6.6 and closed the trading day at $6.73, in the green by 2.75%. The total traded volume for the day was 1,075,739. The stock had closed at $6.55 in the previous days trading.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director officer (COO & CFO) of Orasure Technologies Inc, Spair Ronald H had sold 75,974 shares worth of $760,500 in a transaction dated December 19, 2014. In this transaction, 75,974 shares were sold at $10.01 per share.

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test, OraQuick ADVANCE, OraSure HIV-1 oral specimen collection device, OraQuick HCV rapid antibody test, Intercept oral fluid drug testing system, OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary, DNA Genotek Inc., the Company provides oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.